Regenerative Medicine for Cartilage Market Report 2025

The regenerative medicine for cartilage market size has grown strongly in recent years. It will grow from $4.43 billion in 2024 to $4.68 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to regenerative medicine market resulted from rising prevalence of chronic diseases, emerging markets growth, implementation of the 21st century cures act, rapid growth in aging population, and the improvement in healthcare awareness and expenditure.

The regenerative medicine for cartilage market size is expected to see strong growth in the next few years. It will grow to $5.97 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to rising demand for organ transplantations, growth in healthcare expenditure, technological advancements in regenerative medicines, rising investments in regenerative medicine research, and changes in lifestyles. Major trends in the forecast period include growing use of mesenchymal stem cell technology, increasing research and development on use of novel gene therapy techniques, advancements in technology transfer and clinical translation, rising strategic collaborations, partnerships and agreements, growth and advent of new companies, injectable hydrogel role in cartilage repair as a regenerative medicine, and global research initiatives and funding.

The escalating prevalence of osteoarthritis worldwide is set to be a key driver for the regenerative medicine for cartilage market. Osteoarthritis, a degenerative joint disorder primarily affecting the articular cartilage, is anticipated to impact at least 130 million individuals globally by 2050, as projected by the Arthritis Foundation. Autologous chondrocyte implantation and scaffold implants are among the commonly employed treatments for osteoarthritis. Consequently, the growing incidence of osteoarthritis is expected to fuel the demand for regenerative medicine for cartilage.

The surge in chronic diseases is poised to propel the growth of the regenerative medicine for cartilage market. Chronic diseases, enduring over an extended period and often throughout a person's lifetime, play a pivotal role in the need for medical specialty solutions, including regenerative medicine for cartilage. The prevalence of chronic diseases, particularly those impacting the musculoskeletal system, bodes well for the field of regenerative medicine. According to the World Health Organization, 74% of the 41 million annual deaths globally are caused by non-communicable diseases (NCDs) or chronic diseases. Notably, 17.9 million deaths result from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2 million from diabetes. Consequently, the increasing incidence of chronic diseases is driving the growth of the regenerative medicine for cartilage market.

Emerging trends in regenerative medicine for cartilage include tissue engineering and stem cell therapy. The advancement of tissue engineering technology offers promising prospects for cartilage regeneration. Stem cell therapy, with its advantages over traditional orthopedic treatments, is gaining prominence for reducing knee pain and enhancing knee cartilage regeneration and repair. Technologies such as platelet-rich plasma (PRP) therapy, incorporating growth factors, are utilized to effectively promote tissue regeneration. Market players are actively introducing new technologies to stay competitive in the evolving landscape of regenerative medicine for cartilage.

Major companies in the regenerative medicine market for cartilage are focused on developing bioactive materials to enhance cartilage regeneration and improve treatment outcomes. These bioactive materials are designed to replicate the natural extracellular matrix, thereby promoting cell proliferation, differentiation, and tissue repair. For example, in August 2024, researchers at Northwestern University, a private research university in the U.S., created a bioactive material that successfully regenerated high-quality hyaline cartilage in a sheep model. This biomaterial combines a bioactive peptide that binds to transforming growth factor beta-1 (TGFb-1) with chemically modified hyaluronic acid. This combination facilitates the self-organization of nanoscale fibers, emulating natural cartilage formation and enhancing cellular repair processes. This material holds the potential to prevent knee replacements and treat degenerative diseases.

In November 2023, Smith & Nephew, a UK-based manufacturing firm, acquired CartiHeal for an undisclosed sum. The purpose of this acquisition is to strengthen Smith & Nephew's portfolio in the orthopedic sector, particularly concerning cartilage repair and regeneration. Smith & Nephew aims to improve its capability to meet the growing demand for effective solutions in orthopedic care, ultimately enhancing patient outcomes and solidifying its position in the global medical technology market. CartiHeal is an Israel-based medical technology company specializing in innovative treatments for cartilage and osteochondral defects in joints.

Major companies operating in the regenerative medicine for cartilage market include Smith & Nephew plc, Integra LifeSciences, Stryker Corporation, MiMedx Group, Inc., Zimmer Biomet Holdings Inc., B. Braun Melsungen AG, AbbVie, CONMED Corporation, Arthrex Inc., Baxter International Inc., China Regenerative Medicine International, AstraZenaca, ABLbio, Cellgenix Gmbh, BioTissue Technologies, Corin Group, Medical Import Ltd., Orthonika, Merete, 3di GmbH, Aditus Medical GmbH, Anton Hipp GmbH, AREX SAS, Acelity L.P. Inc., Celgene Corporation, StemCells, Inc, Organogenesis Inc, NuVasive, Inc, Japan Tissue Engineering Co., Ltd, Advantagene, Inc., Mesoblast Ltd, Globus Medical, DePuy Synthes, Cryolife Inc, Johnson & Johnson, Medtronic Plc, Rti Surgical, CartiHeal, Inc., DJO Global Inc., Wright Medical Group, Auxein, Aesculap, Inc, AMEGA Biotech.

Europe was the largest region in regenerative medicine for cartilage in 2024. The regions covered in the regenerative medicine for cartilage market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the regenerative medicine for cartilage market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Regenerative medicine for cartilage involves a treatment administered during surgery to repair damaged knee cartilage using cells produced by the body that can generate cartilage. The process entails obtaining a biopsy to collect chondrocytes, the cells responsible for cartilage production. These chondrocytes are then multiplied in a laboratory setting before being implanted into the injured area as part of the surgical procedure.

The primary types of regenerative medicine for cartilage include cell-based, gene-based, and tissue-based approaches. Cell-based methods typically encompass processes, technologies, or products that involve living cells or are derived from them. They find application in various medical fields such as musculoskeletal, oncology, dental, wound care, among others, and are utilized by different end-users including ambulatory surgical centers, hospitals and clinics, and others.

The regenerative medicine for cartilage market research report is one of a series of new reports that provides regenerative medicine for cartilage market statistics, including regenerative medicine for cartilage industry global market size, regional shares, competitors with regenerative medicine for cartilage market share, detailed regenerative medicine for cartilage market segments, market trends and opportunities, and any further data you may need to thrive in the regenerative medicine for cartilage industry. This regenerative medicine for cartilage market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The regenerative medicine for cartilage market consists of sales of cartilage regeneration, platelet-rich plasma (PRP), and prolotherapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.